

# California Department of Public Health Immunization Updates for Providers

Friday, October 4, 2024

9:00 am – 10:30 am



# Housekeeping

## Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the [CDPH Weekly Immunization Updates for Providers](#).



To be added to the CDPH email messaging listserv for providers, please email your request to [blanca.corona@cdph.ca.gov](mailto:blanca.corona@cdph.ca.gov).

If you have post-webinar-related questions, please email [leslie.amani@cdph.ca.gov](mailto:leslie.amani@cdph.ca.gov).

## Reminder to Panelists:




Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

# Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



Resource links will be dropped into, "Chat"



# Friday, October 4, 2024

No.	Item	Speaker(s)	Time (AM)
1	Welcome, Announcements, and Project Pets	Leslie Amani (CDPH)	9:00 – 9:05
2	California Immunization Registry (CAIR)	Michael Powell (CDPH)	9:05 – 9:10
3	California Bridge Access Program (CA BAP)	Maria Volk (CDPH)	9:10 – 9:20
4	Clinical Update	Caterina Liu, MD (CDPH)	9:20 – 9:30
5	Vaccines for Children (VFC)	Christina Sapad (CDPH)	9:30 – 9:40
6	Vaccines for Adults (VFA)	Lindsay Reynoso (CDPH)	9:40 – 9:45
7	Vaccine Management Updates	Josh Pocus (My Turn) and Maria Volk (myCAvax)	9:45 – 10:00
8	Resources and Q&A	Leslie Amani (CDPH)	10:00 – 10:30

Thank you for attending today's session!



Joey d'Pooch Amani

# Announcements

Leslie Amani, CDPH





# Crucial Conversations Webinar

**Title:** Talking with Families about Fall Immunizations: COVID-19, Flu, RSV

**Description:** Please join Dr. Ilan Shapiro to learn conversational methodologies for effectively talking with families about fall immunizations, including COVID-19, flu, and RSV.

**When:** Tuesday, October 22, 2024


**Time:** 12:00 pm - 1:00 pm (PT)

**Registration link:** [Crucial Conversations Webinar Registration](#)



# CDPH EZIZ Provider Listserv

To be added to the CDPH EZIZ email messaging listserv for providers, please email, Blanca Corona at, [blanca.corona@cdph.ca.gov](mailto:blanca.corona@cdph.ca.gov)



**CDPH | EZIZ Update**

October 2, 2024

### Latest Updates and Resources

**In this message:**

1. Upcoming CDPH Immunization Updates for Providers
2. CA Bridge Access Program (BAP) 2024 - 2025 Letter
3. The Public are Looking for Providers, Make Your Presence Known!
4. Mpox Provider Resources

### CDPH Immunization Updates for Providers

Please join CDPH **Friday, October 4, from 9:00 am - 10:30 am (PT)** for the CDPH Immunization Updates for Providers webinar, occurring every other Friday. CDPH subject matter experts will provide updates, resources, and answer attendees' vaccine questions.

This week meet the CDPH "Pets of the Project" and see our furry companions that help us during our webinars, as well as learn about important RSV updates from Dr. Caterina Liu.

Please ensure someone from your staff attends to hear relevant and timely updates.

**Register for the webinar on Friday, October 4, 2024, 9:00 am - 10:30 am (PT).**





# CDPH Office of Communications Newsletter



[RSV Communications Toolkit](#)



[COVID-19 Testing](#)

[Sign up for this newsletter](#)

Sign up for [CDPH News Releases](#)

Sign up for [CDPH Policy Alerts](#)

CDPH [Office of Communications Toolkits](#)

[CDPH News Release](#) archive





I am looking for

I am a

Programs

A-Z Index

Home | A New Look for CDPH

# A NEW LOOK FOR CDPH



About CDPH

The Director's Office

What is Public Health?

Future of Public Health

Language Access Plan

**A New Look for CDPH**

Translations

Contact CDPH

At the California Department of Public Health (CDPH), our mission is to advance the health and well-being of California's diverse people and communities. We work so that every Californian has the knowledge, resources and support to lead a healthy life. We're excited to introduce a new visual identity (and logo) to reflect this commitment.

## The Power of Community: Shaping Our New Identity

The journey to CDPH's new visual identity was a long one. We sought out and listened to the voices of the people we serve. We surveyed more than 2,000+ Californians across the state with diverse identities and languages. We received feedback from CDPH employees, leaders and local health department partners. This input was invaluable.

Our new logo and brand identity represent California's diverse peoples and communities.

# CDPH A New Look!

Our new logo and brand identity represent California's diverse peoples and communities.



The state icon symbolizes the communities and regions of California coming together.



The bold colors represent the diversity of our people.



The connecting lines represent unity, optimism and sun rays for a brighter future.

## Trust, Unity and Innovation: The Heart of Who We Are

This new identity isn't only about the work CDPH is doing today — it's about the future of public health in California. Our new identity reflects our work to bring modern and innovative approaches to improve the health of all Californians. It represents our ongoing commitment to foster deeper connections with the communities we serve. With this bold and colorful identity, we are reintroducing Californians to CDPH and the more than 200 programs and services we provide every day. Our new identity unites all CDPH programs and services. It's a sign you can trust, backed by our professional team dedicated to our mission.

## CDPH: A New Look!



# Commercially Available Jynneos in California Provider and Health System Access

## Provider and Health System Access to Commercially Available JYNNEOS Vaccine in California

### Background:

The purpose of this document is to share information with California health care providers about offering JYNNEOS vaccine through the commercial market to persons at risk for mpox. JYNNEOS is approved by the U.S. Food and Drug Administration (FDA) for prevention of smallpox and mpox disease in adults 18 years and older at high risk for infection, and it is currently on the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) routine immunization schedule for certain individuals at risk for mpox.

### CDC ACIP recommendations for mpox vaccination

As of October 2023, ACIP recommends vaccination with the 2-dose JYNNEOS vaccine series for persons aged 18 years and older at risk for mpox, which includes the following:

1. Gay, bisexual, and other men who have sex with men, transgender people, or nonbinary people who, in the past 6 months, have had one of the following:
  - New diagnosis of  $\geq 1$  sexually transmitted disease
  - More than one sex partner
  - Sex at a commercial venue
  - Sex in association with a large public event in a geographic area where mpox transmission is occurring.
2. Sexual partners of persons with the risks described above
3. Persons who anticipate experiencing any of the above
4. Persons at risk for occupational exposure to orthopoxviruses:
  - a. Research laboratory personnel working with orthopoxviruses
  - b. Clinical laboratory personnel performing diagnostic testing for orthopoxviruses
  - c. Orthopoxvirus and health care worker response teams designated by appropriate public health and antiterror authorities.

In addition, CDC also recommends vaccination for people traveling to countries with [clade I outbreaks](#) who anticipate any sexual activity, regardless of gender identity or sexual orientation.

Any person at risk for mpox infection should receive the 2-dose series, 28 days apart. People who received only one vaccine dose (and were never diagnosed with mpox), should receive the 2nd dose at 28 days or as soon as possible thereafter, regardless of the amount of time that has lapsed since the first dose; the series should not be restarted.

Most people who meet the above criteria and have health insurance should have access to JYNNEOS vaccine for free. In addition, appointments are now available at several pharmacy chains (e.g., [CVS](#), [Rite Aid](#), [Walgreens](#)) in California. Check with your local pharmacy to inquire about JYNNEOS vaccine availability. Further details about coverage for insured persons and options for uninsured or underinsured persons are below.

### JYNNEOS Administration in Children <18 Years of Age

JYNNEOS is also available for use as post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) for children and adolescents under 18 years determined to be at high risk for mpox infection under the [Emergency Use Authorization \(EUA\)](#) issued by the US Food and Drug Administration on August 9, 2022. [CDC clinical considerations for mpox in children and adolescents in the U.S.](#) are available. For more information about vaccination, please visit: [Mpox Vaccine Considerations](#). Check with the health insurer about reimbursement status.

### Coverage Options for JYNNEOS Vaccine for Providers & Health Systems

#### For Insured Individuals

##### Private Insurance

Individual and employer-sponsored private health plans subject to the Affordable Care Act's preventive services coverage standards must provide coverage for individuals to receive vaccines that ACIP recommends without charging a copayment or coinsurance when provided by an in-network provider, even for patients who have not met their yearly deductible. When ACIP recommends a new vaccine, there is a one-year lag for when the coverage requirement starts for that vaccine. Since ACIP recommended the JYNNEOS vaccine for mpox in October 2023, health plans must update their coverage policies once a new plan year starts after October 2024. However, many health insurers have already started covering JYNNEOS vaccine without cost sharing, and as of September 2024, the California Department of Public Health was unaware of denials to cover the JYNNEOS vaccine.

## Commercial Jynneos in CA: Providers for Healthcare Systems Access





# CDPH Pets of the Project



Lulu Allen



Finn Grey



Herbie McNitt



Lucy Cappelluti




Taco Leung




Luci Goose and  
Cricket Zavala





Colby Jack Gamboa

Pets can provide social, physical, mental and emotional boosts!



Maggie Evans



Bear Yen




Mitzi Mae Czajkowski



[Cleveland Clinic: The Health Benefits of Pets](#)




Luna Villagomez







In Memory of:  
Riley Fowler



Zoe Fowler

Flag Cate



Frida (dog) and Hexa (cat) Mallen

**Healthy Benefits**

- Stress Relief
- Maintaining a Routine
- Being Social








In Memory of:  
Lacey Pine



Jackson  
Roberts


The love and  
presence of a pet  
can calm us!



Arrow Gandhi



Bentley  
Roberts




In Memory of: Bella  
and Wizard Wood



Stella  
Greenblatt







# California Immunization Registry (CAIR)

Michael Powell, CDPH





# CAIR2 Release Roadmap

## Past Release

September 18, 2024 (2.8.18)

### Sprint 16

#### User Interface

- ✓ Add Vivotif manufacturer to dropdown on Manage NDC
- ✓ Add RabAvert manufacturer Bavarian Nordic to dropdown on Manage NDC screen
- ✓ Trivalent Flu Vaccines Codes for 2024/2025
- ✓ Quadrivalent Flu Vaccines Codes for 2024/2025

#### Data Exchange

- ✓ Source of Immunization for Historical Doses
- ✓ Add PCV21
- ✓ Trivalent Flu Vaccines Codes for 2024/2025
- ✓ Quadrivalent Flu Vaccines Codes for 2024/2025
- ✓ New code sets for Havrix, Pfizer Comirnaty & Abrysvo

#### Technical

- ✓ Merge parsing research & cleanup
- ✓ Update pending immunization cron job

## Current

October 16, 2024 (2.8.19)

### Sprint 17

#### User Interface

- ✓ PPSV23 bug in children under 5 yo
- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90

#### Data Exchange

- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90
- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version
- ✓ A dose amount of '1.0' is returned in RXA-6 for all VXP messages
- ✓ ACK fixes
- ✓ Allow "Md" to the name fields

#### Technical

- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version

## Future

### Upcoming Releases

#### User Interface

- ✓ Add New vaccine Vaxchora
- ✓ Add New Avian Influenza CVX codes
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown

#### Data Exchange

- ✓ Add New vaccine Vaxchora
- ✓ Add New Avian Influenza CVX codes
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown
- ✓ Update RSP RXA-6 and RXA-7

# CAIR2 Notes

- Legislative Bills
  - Signed on 9/28/2024
    - [SB 957](#) Updates HSC 120440 to collect voluntarily provided SOGISC data from adults.
    - [SB 1016](#) Requires collection of detailed demographic information on specified Hispanic groups.
- National Drug Codes (NDCs)
  - New COVID NDCs added to CAIR
  - All records re-submitted to CAIR
  - Staff assigned to work on pending/duplicate records

# My DVR Release Roadmap

## Past Release

September 4, 2024 (UR74)

### Unified Release 74

#### DVR Front End

- ✓ Upgrade to newest Evaluator version to support new Flu/MenABCWY vaccines
- ✓ Support for new My Turn vaccines (Shingles, Pneumonia) added to overdue/due soon banner on the full DVR

#### DVR Integration

- ✓ Role Based Access Control (RBAC) for DVR in Databricks
- ✓ Consume data from consolidated IRIS Schema

#### Staff Remediation Tool (SRT)

- ✓ Optimize backend SMS precheck process
- ✓ Refactor SMS comms logic

#### Virtual Assistant Tool (VAT)

- ✓ Refined user stories for VAT font consistency and removal of Snowflake function in VAT flow

## Current

October 1, 2024 (UR75)

### Unified Release 75

#### DVR Front End

- ✓ Renew frontend certificate for generating COVID-19 QR codes and California Immunization Records on mobile devices
- ✓ Enhance COVID-19 Vaccine Record retrieval process for unsupported CVX codes

#### DVR Integration

- ✓ Continue preparations to migrate DVR Dashboards to Power BI
- ✓ Increase fault tolerance on Databricks API calls
- ✓ Cleanup historical files for delta tables
- ✓ Upgrade ADF – Snowflake Linked Service

#### Staff Remediation Tool (SRT)

- ✓ Optimize backed processes for VAT image deletion and SMS Returns utilizing Azure Functions
- ✓ Migrate remaining SRT dashboards to Power BI

#### Virtual Assistant Tool (VAT)

- ✓ Ensure formatting consistency throughout VAT

## Future

(UR76+ until EOY)

### Upcoming Unified Releases

#### DVR Front End

- ✓ Release Google Wallet integration for android users to save CA Immunization Record to mobile devices
- ✓ Enhance DOB field for usability
- ✓ FAQ page search feature to enable fuzzy matching across all pages
- ✓ Evaluator Series and Booster dose logic enhancements to the CA Immunization Record

#### DVR Integration


- ✓ Optimize backend Databricks API calls and enhance alerts for merged records
- ✓ Repoint views in DVR pipelines

#### Staff Remediation Tool (SRT)

- ✓ Enhance User Management page to add/inactive users
- ✓ Ticket History enhancement to display all changes made to a ticket
- ✓ Consolidate CVX codes to backend mapping table that will capture any new CVX code

#### Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring




# California Bridge Access Program

Maria Volk, CDPH



# CA Bridge Access Program: CDPH Program Letter



**CDPH** State of California—Health and Human Services Agency  
California Department of Public Health

**TOMÁS J. ARAGÓN, M.D., Dr.P.H.**  
Director and State Public Health Officer

**GAVIN NEWSOM**  
Governor

October 2, 2024 IZB-FY-24-25-02

TO: California Bridge Access Program (CA BAP) Providers

FROM: Robert Schechter, M.D., Chief, Immunization Branch *Robert Schechter*  
Division of Communicable Disease Control,  
Center for Infectious Diseases

SUBJECT: CA BAP 2024 – 2025 COVID-19 Vaccine Ordering

**BACKGROUND:** The California Bridge Access Program (CA BAP) has been extended for existing BAP providers to offer no-cost COVID-19 vaccines to uninsured and underinsured adults aged 19 years and older.

**Program Participation**  
Participation, eligibility, and all other CA BAP requirements are unchanged. BAP [Provider Participation agreements](#) have been extended, and no action from current providers is required. As available funds will purchase fewer doses than last year, CDPH is limiting participation primarily to existing (not new) providers. For additional resources, see the [CA BAP Provider Participation agreement](#) and [CA BAP Requirements](#).

**COVID-19 Vaccine Supply**  
The total CA BAP supply for the 2024–2025 season will be about 69,000 doses. Doses have been allocated to each Local Health Department to support ordering for active CA-BAP provider, including Public Health Clinics and Community Health Centers. The Initial doses allocated to each jurisdiction (67% of total) are based on doses initially available. Additional allocations will be added as supplies become available.

All authorized 2024-2025 COVID-19 vaccines are available through CA BAP, including:

- **Spikevax (Moderna) Single Dose Prefilled Syringe- 10 Per Box** NDC: 80777-0110-93
- **Novavax Single dose prefilled Syringe - 10 Per Box** NDC: 80631-0107-10
- **Comirnaty (Pfizer) Single Dose Syringes- 10 Per Box** NDC: 00069-2432-10

Detailed information, including packaging, shipping, storage, and administration, is available in the updated [COVID-19 Vaccine Product Guide](#).

**IMPORTANT: 2023 – 2024 COVID-19 Vaccines are no longer authorized and should not be administered.** Expired doses need to be returned to McKesson and reported in myCAvax. Visit [Reporting and Return of Nonviable Vaccines webpage](#) for additional information.

Immunization Branch / Division of Communicable Disease Control  
850 Marina Bay Parkway, Bldg. P, 2<sup>nd</sup> Floor, Richmond, CA 94804  
(510) 620-3737 • FAX (510) 620-3774 • Internet Address: [www.cdph.ca.gov/immunizedca](http://www.cdph.ca.gov/immunizedca)

**PHAB**  
Partnership for Health Advancement

CDPH Program Letter from Robert Schechter, MD, Chief, IZB, DCDC, CID:

Includes:

- CA BAP COVID-19 Vaccine Ordering
- Program Participation
- COVID-19 Vaccine Supply
- COVID-19 Product Information
- Resources
- And more...


[CDPH Program Letter for CA BAP Providers](#)






# California Bridge Access Program (CA BAP) Extension

The CA BAP has been extended to continue to provide COVID-19 vaccines at no-cost to underinsured and uninsured adults aged 19 years and older during the 2024 – 2025 Respiratory Season, as supply permits.



Provider ordering and management is supported via the current CA Bridge Access Program (CA BAP) system structure in myCAvax.



CA BAP locations are no longer required to report locations in vaccines.gov; however, are encouraged to Opt-in to My Turn Vaccine Locator (Public-facing).

# CA BAP Funding and Ordering FFY 2023 – 2024 and 2024 – 2025

**Funding:** Section 317 COVID-19 funding supports ordering for vaccines provided through the California Bridge Access Program.

FFY	317 Funds	Overall Vaccine Ordering Limits	Ordered Doses	% Budget Consumed
2023 – 2024	34M	380K	72K	34%
2024 – 2025	5.9M	69K	12,460*	19%*

\*As of 10/02/2024



# CA BAP 2024 – 2025 Allocations


Allocation for 2024 – 2025

- **Overall season allocations ~69K doses**
- **Initial season available doses ~ 46K (67% of overall BAP extension doses)**, consisting mainly of Moderna and Pfizer; with limited number of Novavax doses.
- Additional allocations will be added as supply becomes available.


# California Bridge Access Program (CA BAP) Providers

Currently **938 active BAP providers** may order COVID-19 vaccines via myCavax.

As part of the extension, open enrollment is not available; however, CDPH will reach out to select community pharmacies to determine addition for CA BAP



# California Bridge Access Program (CA BAP) Extension Launch Timeline



**Note:** BAP orders approved by LHDs on 9/27 were transmitted to CDC the same day to get orders in ahead of CDC's VTrckS backout.

# 2024–2025 Weekly Ordering & Distribution Cadence Calendar

California BAP Vaccination Program(Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
September 23	24	25 <b>CA BAP Ordering Goes Live in myCAvax!</b>	26	27
				<b>Provider Order (submit by 5PM) *</b>
30	October 01	02	03	04
<b>VTckS Downtime – No Vaccine Deliveries</b>				Vaccine Delivery – McKesson (Moderna/Novavax) & Pfizer Direct Ship Processed Wednesday
		<b>LHD Approval (By 12PM)</b>		<b>LHD Approval by 12PM</b>
		<b>CDPH Transmits to CDC</b>		<b>CDPH Transmits to CDC</b>
		<b>Provider Order (submit by 5PM)</b>		
07	08	09	10	11
	COVID-19 Vaccine Delivery – McKesson (Moderna/Novavax) & Pfizer Direct Ship Processed Friday *Previous week			Vaccine Delivery – McKesson (Moderna/Novavax) & Pfizer Direct Ship Processed Wednesday
	Vaccine Delivery – McKesson (Moderna/Novavax) & Pfizer Direct Ship Processed Tuesday *Previous week			
		<b>LHD Approval by 12PM</b>		<b>LHD Approval by 12PM</b>
		<b>CDPH Transmits to CDC</b>		<b>CDPH Transmits to CDC</b>
<b>Provider Order (submit by 5PM)</b>		<b>Provider Order (submit by 5PM)</b>		



- Order Processing is dependent on the date of LHD approval. If an approval deadline is missed, the order will be processed the following CDPH Transmission date.
- \*Adjusted Provider order submission deadline for VTckS downtime the following week
- Delivery windows are dependent on provider’s days/hours of operation. Update hours in myCAvax for any holiday or temporary closures.
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

# 2024–2025 Weekly Ordering & Distribution Cadence Calendar

California BAP Vaccination Program(Providers/LHDs)

Week 1

Monday	Tuesday	Wednesday	Thursday	Friday
				COVID-19 Vaccine Delivery <b>(Processed Wednesday)</b> – McKesson (Moderna/Novavax) & Pfizer Direct Ship
		LHD Approval by 12PM		LHD Approval by 12PM
		CDPH Transmits to CDC		CDPH Transmits to CDC
Provider Order (submit by 5PM)		Provider Order (submit by 5PM)		

Week 2

Monday	Tuesday	Wednesday	Thursday	Friday
	COVID-19 Vaccine Delivery <b>(Processed Friday Previous Week)</b> – McKesson (Moderna/Novavax) & Pfizer Direct Ship			COVID-19 Vaccine Delivery <b>(Processed Wednesday)</b> – McKesson (Moderna/Novavax) & Pfizer Direct Ship
	COVID-19 Vaccine Delivery <b>(Processed Wednesday Previous Week)</b> – McKesson (Moderna/Novavax) & Pfizer Direct Ship			
		LHD Approval by 12PM		LHD Approval by 12PM
		CDPH Transmits to CDC		CDPH Transmits to CDC
Provider Order (submit by 5PM)		Provider Order (submit by 5PM)		

- Order Processing is dependent on the date of LHD approval. If an approval deadline is missed, the order will be processed the following CDPH Transmission date.
- Delivery windows are dependent on provider’s days/hours of operation. Update hours in myCAvax for any holiday or temporary closures.
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.



# Updated: CA BAP Resources

- EZIZ's [CA BAP Overview](#) and [Resources](#) webpages
- [CA BAP Requirements at a Glance](#)
- [CA BAP Provider Operations Manual](#) (CA BAP POM)







Luna Liu


# Clinical Update

Caterina Liu, MD, CDPH






# Emily's Story



Emily shares the [heart-breaking story](#) of her young daughter who was hospitalized with RSV and ultimately succumbed to the disease. She wants to use her daughter's story to increase awareness about RSV, so she can help other families prevent such a tragedy.

"I called my parents, and I said you guys need to get here soon; like, she's not okay..."

# Weekly Rates of Respiratory Virus-Associated Hospitalizations for Infants <1 year old, Oct. 2023-Sept. 2024



At its peak in the 2023 – 2024 season (week ending Dec. 30, 2023), **RSV accounted for nearly 80% of all infant respiratory hospitalizations.**

Data last updated September 27, 2024, [Respiratory Virus Hospitalization Surveillance Network \(RESP-NET\)](#) | [RESP-NET](#) | [CDC](#)

# Early Estimate of Nirsevimab Effectiveness for Prevention of RSV Hospitalization Among Infants Entering their First RSV Season, October 2023 – February 2024



**Nirsevimab was **90% effective** at protecting infants from RSV-associated hospitalization\***

**Clinicians, talk to parents about nirsevimab, a preventive antibody**


\* Early estimates from the New Vaccine Surveillance Network, October 2023–February 2024

 [bit.ly/mm7309a4](https://bit.ly/mm7309a4)  
MARCH 7, 2024

**MMWR**

[Early Estimate of Nirsevimab Effectiveness for Prevention of RSV–Associated Hospitalization Among Infants Entering Their First RSV Season — Oct 2023–Feb 2024 | MMWR \(cdc.gov\); ACIP June 2024 slides: Summary of nirsevimab effectiveness in infants](#)

# RSV Immunization – Maternal/Pediatric



For most infants, administration of both products is **not** needed.  
[CDC Clinical Guidance for Infants and Young Children](#)



# Maternal RSV Vaccination and Receipt of Nirsevimab by Infants Aged <8 Months — United States, April 2024

## Survey: Almost half of young infants didn't benefit from RSV immunization last season\*



ACIP recommends either:

- Maternal RSV vaccination (32-36 weeks); or
- RSV antibody for young infants

**We are entering RSV season. Clinicians, talk to pregnant patients and new parents about protecting young babies from RSV**

[bit.ly/mm7338a2](https://bit.ly/mm7338a2)

SEPTEMBER 26, 2024

\* Internet survey of 2,263 current and recently pregnant women – 2023-24 RSV season

**MMWR**

**MMWR: Maternal Respiratory Syncytial Virus Vaccination and Receipt of RSV Antibody (Nirsevimab) by Infants Aged <8 Months**

# Maternal RSV Vaccination and Receipt of Nirsevimab by Infants Aged <8 Months — United States, April 2024


- Survey from 3/26/2024 – 4/11/2024.
- Sample: 2,263 women, reported being pregnant since 8/1/2023.

## Results:

- Maternal RSV vaccine coverage: 33%
- Nirsevimab coverage among infants: 45%
- 56% of infants protected by maternal RSV, nirsevimab, or both.
- **Nearly half of women surveyed did not report provider recommendation of maternal or infant RSV immunization.**
- Provider recommendation associated with higher coverage.

[MMWR: Maternal Respiratory Syncytial Virus Vaccination and Receipt of RSV Antibody \(Nirsevimab\) by Infants Aged <8 Months](#)


# Reason Reported for Not Receiving Maternal RSV Immunization



MMWR: Maternal Respiratory Syncytial Virus Vaccination and Receipt of RSV Antibody (Nirsevimab) by Infants Aged <8 Months



# Reason Reported for Not Receiving Infant RSV Immunization



MMWR: Maternal Respiratory Syncytial Virus Vaccination and Receipt of RSV Antibody (Nirsevimab) by Infants Aged <8 Months

# New Provider Resource: Infant RSV Prevention At-A-Glance (CDC)

## Respiratory Syncytial Virus vaccines (RSV)

### Options for Infant RSV Prevention At-a-Glance

Two immunization products are available for the prevention of severe Respiratory Syncytial Virus (RSV) disease in infants: maternal RSV vaccine and infant RSV monoclonal antibody. All infants should be protected against severe RSV disease through use of one of these products.

*Either maternal RSV vaccination or use of RSV monoclonal antibody in the infant is recommended. Administration of both products is not needed for most infants.*

**Maternal RSV vaccination: Use ONLY Pfizer RSVPreF vaccine (trade name Abrysvo™)**

#### Maternal RSV Vaccine

RSVPreF vaccine (trade name Abrysvo™) is recommended for people during weeks 32 through 36 of pregnancy, using seasonal administration, to prevent severe RSV disease in infants. In clinical trials, there was a small increase in the number of preterm birth events in vaccinated pregnant people after vaccination. It is not clear if this is a true safety problem related to RSV vaccine or if this occurred for reasons unrelated to vaccination.

#### Infant RSV Monoclonal Antibody\*

RSV monoclonal antibody (generic name nirsevimab, trade name Beyfortus™) is recommended for the following:

- Infants less than 8 months of age born during or entering their first RSV season if:
  - Mother did not receive maternal RSV vaccine or it is unknown if mother received RSV vaccine
  - OR
  - Infant was born less than 14 days after maternal RSV vaccination<sup>1</sup>

In rare circumstances, nirsevimab may be considered for infants born to mothers vaccinated 14 or more days before birth when the health care provider believes the potential incremental benefit is warranted. These situations include, but are not limited to:

- Infants born to mothers who might not have mounted an adequate immune response to vaccination (e.g., people with immunocompromising conditions)
- Infants born to mothers who have conditions associated with reduced transplacental antibody transfer (e.g., people living with HIV infection)
- Infants who might have experienced loss of maternal antibodies, such as those who have undergone cardiopulmonary bypass of extracorporeal membrane oxygenation (ECMO)
- Infants with substantial increased risk for severe RSV disease (e.g., hemodynamically significant congenital heart disease, intensive care admission with the requirement for oxygen at hospital discharge)

- Some infants and children aged 8 through 19 months who are at increased risk of severe RSV disease entering their second RSV season.

- American Indian/Alaska Native children
- Children with chronic lung disease of prematurity who require medical support during the six months before the start of their second RSV season
- Children with severe immunocompromise
- Children with severe cystic fibrosis

\*Note: A different monoclonal antibody, palivizumab, is used in children under 24 months of age with certain conditions that place them at high risk for severe RSV disease. Please see [AAP guidelines for palivizumab](https://www.aap.org/clinical-guidance/palivizumab). AAP has published considerations on the use of nirsevimab and palivizumab: <https://publications.aap.org/feedback/resources/25373>. Children who have received nirsevimab should not receive palivizumab during the same RSV season.

<sup>1</sup>From time of maternal vaccination, at least 14 days are needed for the development and transplacental transfer of maternal antibodies to protect the infant.

## Clinical Considerations for Use of Maternal RSV Vaccine or Infant RSV Monoclonal Antibody

(Administration of both products is not needed for most infants)

Product	Maternal RSV Vaccine	RSV Monoclonal Antibody
Description	RSVPreF vaccine Trade name: Abrysvo™	Generic name nirsevimab Trade name: Beyfortus™
Immunity	Mother – Active immunity Infant – Passive immunity	Passive immunity
Duration of Protection	Approximately 3 to 6 months for infant	Approximately 5 months or more
How Supplied	A kit that includes a vial of lyophilized antigen component, a prefilled syringe containing sterile water diluent, and a vial adapter. The lyophilized antigen component is reconstituted with the sterile water diluent to form a single dose.	Single dose pre-filled syringe with a purple (for 50 mg dosage) or light blue (for 100 mg dosage) plunger rod. No reconstitution needed.
Recommended Dosage	0.5 mL Currently recommended for administration as a single dose. It is not yet known whether additional doses might be needed in later pregnancies.	<b>Age less than 8 months</b> • Less than 5 kg: 50 mg (0.5mL) • 5 kg and greater: 100 mg (1mL) <b>Age 8 through 19 months<sup>1</sup></b> • 200 mg (administered as two IM injections)
Number of Doses	One	One <sup>2</sup>
How Administered	IM injection	IM injection
Coadministration	Can be administered without regard to timing of other routine immunizations, including simultaneous administration	Can be administered without regard to timing of other routine immunizations, including simultaneous administration
Gestation or Age for Immunization	32 through 36 weeks	• Less than age 8 months depending on mother's RSV vaccination status • Ages 8 through 19 months if at increased risk for severe RSV disease. <sup>1</sup>
When to Administer (Seasonality)	Beginning of September through end of January in most of the continental United States.  In jurisdictions with RSV seasonality that differs from most of the continental United States, including Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of maternal RSV vaccination.	Beginning of October through end of March in most of the continental United States.  In jurisdictions with RSV seasonality that differs from most of the continental United States, including Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, and U.S. Virgin Islands, healthcare providers should follow state, local, or territorial guidance on timing of nirsevimab administration.
Contraindications (Product Should Not Be Administered)	History of severe allergic reaction (e.g., anaphylaxis) to any component of the maternal RSV vaccine	History of severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of nirsevimab

## Clinical Considerations for Use of Maternal RSV Vaccine or Infant RSV Monoclonal Antibody

(Administration of both products is not needed for most infants)

Product	Maternal RSV Vaccine	RSV Monoclonal Antibody
Precautions (Administration Should Typically Be Deferred)	The presence of a moderate or severe acute illness, with or without a fever.	The presence of a moderate or severe acute illness, with or without a fever.
Safety	<ul style="list-style-type: none"> <li><b>Local and systemic reactions</b> In clinical trials, the most common reactions after maternal RSV vaccine in pregnant people were pain at the injection site, headache, muscle pain, and nausea.</li> <li><b>Severe allergic reactions</b> As with any medicine or vaccine, there is a remote chance of RSV vaccine causing a severe allergic reaction</li> <li><b>Preterm birth</b> In clinical trials, among people who were vaccinated during weeks 24 through 36 weeks of pregnancy, more preterm births were reported among maternal RSV vaccine recipients than among placebo recipients. This difference was not statistically different. Available data are insufficient to establish or exclude a causal relationship between preterm birth and maternal RSV vaccine. To reduce the potential risk of preterm birth when administering maternal RSV vaccine, FDA approved the vaccine for use during weeks 32 through 36 of pregnancy. The vaccine studies did not include people who already had a higher risk of preterm births.</li> <li><b>Hypertensive disorders of pregnancy</b> Although not common, in the clinical trials, hypertensive disorders of pregnancy (including pre-eclampsia) occurred in 1.8% of pregnant people who received the RSV vaccine compared to 1.4% of pregnant people who received a placebo.</li> </ul>	<ul style="list-style-type: none"> <li><b>Local and systemic reactions</b> In clinical trials, the most common adverse events after nirsevimab were rash and injection-site reactions, each occurring in &lt;1% of infants and young children.</li> <li><b>Severe allergic reactions</b> As with any medicine or vaccine, there is a remote chance of nirsevimab causing a severe allergic reaction.</li> <li><b>Serious adverse event</b> The incidence of serious adverse events was not increased in the nirsevimab arm compared with that in the placebo arm. No serious allergic reactions or immune complex disease were reported in the clinical trials.</li> </ul>

<sup>1</sup>Children 8-19 months who are at increased risk of severe RSV disease (American Indian and Alaska Native children; children who are severely immunocompromised; children with cystic fibrosis with severe disease; and children with chronic lung disease of prematurity who require medical support during the six months before the start of their second RSV season) should receive nirsevimab 200 mg dose administered as two IM injections (2 x 100 mg light blue plunger rod) shortly before the start of their second RSV season.

<sup>2</sup>One dose for each RSV season except for children undergoing cardiac surgery with cardiopulmonary bypass where an additional dose is recommended as soon as the child is stable after surgery. See [label \(fda.gov\)](https://label.fda.gov)



# RSV Immunization – Maternal/Pediatric Resources

[RSV Immunization for Children 19 Months & Younger | CDC \(healthcare providers\)](#)

[Immunizations to Protect Infants | RSV | CDC \(public\)](#)

[IMM-1480 Nirsevimab Guide to Prevent Severe RSV in Infants & Toddlers \(eziz.org\)](#)

[Use of the Pfizer RSV Vaccine During Pregnancy: ACIP Recommendations 2023 | MMWR \(cdc.gov\)](#)

[Nirsevimab for the Prevention of RSV in Infants/Children: ACIP Recommendations 2023 | MMWR \(cdc.gov\)](#)

# COVID-19 Vaccine Reminder

- All 2023 – 2024 COVID-19 vaccines are no longer authorized and should not be administered.
  - If a deauthorized product (e.g., a 2023-2024 COVID-19 vaccine) is administered, report the error to [VERP](#). For more info: [VAERS/VERP/MedWatch Jobaid](#).
  - A 2024-2025 COVID-19 vaccine should be given at least 2 months since the last dose of any COVID-19 vaccine. See [CDC Guidance for Administration Errors](#).

## [Interim Clinical Considerations for Use of COVID-19 Vaccines \(CDC\)](#) [Staying Up to Date with COVID-19 Vaccines](#)

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2024-25 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8* weeks 1 ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 4-8 weeks 1 If ≥2 prior doses then: ≥8 weeks 1
5 – 11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months <b>2024-25 Formulation:</b> Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months <b>2024-25 Formulation:</b> Moderna/Pfizer/Novavax
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax	1st Dose → 3-8 weeks** → 2nd Dose	

\* See [CDC recommendations](#) for children transitioning from a younger to older age group  
 † Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.  
 \*\* An 8-week interval may be preferable for some people, especially for males 12-39 years.  
 ‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).  
 ^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

COVID-19 Vaccine Timing Guide: [English](#), [Spanish](#)

# Vaccines for Children (VFC)

Christina Sapad, CDPH



# Vaccines for Children (VFC) Program Requirement: Offer All ACIP Recommended Vaccines

- The Vaccines for Children Program is an entitlement program (a right granted by law) for eligible children, ages 18 and younger.
  - **The VFC eligible child is entitled to receive all ACIP recommended immunizations.**
- “Order all ACIP-recommended vaccines (including flu and special-order vaccines) to meet the needs of the total VFC-eligible patient populations reported for the VFC PIN.” (VFC Program Provider Agreement Addendum #8A)
- “Administer all VFC-supplied vaccines at the approved practice address for the VFC PIN; do not refer patients to other facilities where they might be charged for vaccine administration.” (PAA #15A)
  - **The VFC Program’s goal is to reduce barriers to vaccination, and ensure children receive all the recommended vaccine doses within their medical home.**
- Flu and COVID-19 vaccines are recommended for patients 6-months of age and up.



Provider Comments

Spoke with VFC representative--states that I need to address COVID vaccine ordering in order for flu vaccine order to be accepted. Our office has not had any demand for COVID vaccines and very low demand last year. Per our supervisor and pediatrician, no COVID vaccine to be ordered at this time.

- It is a VFC Program requirement to offer all ACIP recommended vaccines to your patient population. Order doses to have on-hand, regardless of anticipated low demand, should a patient come in who needs the vaccine.
- Seasonal doses remaining at the end of the season, are typically not considered a negligent loss.
- The VFC Program may send orders back in “Corrections Needed” status to give clinics an opportunity to request seasonal immunizations, but we would not reject an order strictly if it is missing certain vaccines. We may follow-up with the clinic to address any barriers to offering certain immunizations.

Provider Comments

i am not order covid cause i still have some

- All 2023-2024 COVID-19 vaccine formulations have been deauthorized and should no longer be administered.
- Submit a return/waste form for any remaining 2023-2024 COVID-19 vaccine inventory and submit a request for the 2024-2025 COVID-19 vaccines.

Provider Comments

██████ does not plan on ordering covid vaccines as we have sister sites we can send our patients to.

The VFC Program's goal is to reduce barriers to vaccination, and ensure children receive all the recommended vaccine doses within their medical home. Do not refer patients to other facilities where they might be charged for vaccine administration.

Provider Comments

we do not wish to order covid or rsv vaccine

- It is a VFC Program requirement to offer all ACIP recommended vaccines to your patient population. Order doses to have on-hand, regardless of anticipated low demand, should a patient come in who needs the vaccine.
- Seasonal doses remaining at the end of the season, are typically not considered a negligent loss.
- Minimum order size for COVID-19 vaccine is 10 doses, and for nirsevimab is 5 doses.

Provider Comments

Beyfortus 50mg and Beyfortus 100mg do not need at this time, we currently have a qty of 9 for both doses

Any remaining unexpired nirsevimab doses from the 2023-2024 RSV season can still be used this season. Order more nirsevimab to meet your patient needs. Ex. Look at vaccine doses you administer to babies, such as PCV or Rotavirus vaccines, or patients in the eligible age for RSV.

# Respiratory Immunization Ordering

- Flu vaccine available for ordering as of 9/5
  - VFC will continue to allocate flu doses as more product is received at McKesson
- COVID-19 vaccine available for VFC ordering as of 9/6
  - Novavax is now available for COVID-19 orders!
- Nirsevimab immunizations available for VFC ordering as of 9/6
  - Nirsevimab allocations have been given to all VFC Providers, with increases for those who have used most of their prior allocations.
    - CDC will provide California with bi-weekly threshold top-offs of nirsevimab. CDC will continue to top-off these thresholds, as long as doses are ordered.
  - 7,695 doses of the 50mg and 14,475 doses of the 100mg nirsevimab products have been processed.
- ABRYSVO™ (maternal RSV vaccine) is now available to order through the VFC Program.

**VFC Update**  
Vaccines for Children Program  
September 26, 2024

## RSV Vaccine for Pregnant People (Abrysvo™) Now Available for Ordering Through the VFC Program

Dear VFC Provider,

The Respiratory Syncytial Virus (RSV) maternal vaccine (Abrysvo™) is now available again for ordering through the Vaccines for Children (VFC) Program. RSV vaccine (Abrysvo™) is recommended for pregnant people during 32 through 36 weeks gestation, using seasonal administration (September through January), to prevent RSV lower respiratory tract infection in infants. Through the VFC Program, Abrysvo™ is intended for use among your VFC-eligible pregnant patients 18 years of age or younger.

Submit your request for Abrysvo™ on the routine VFC vaccine order form in myCAvax, even if it is not time to place your routine VFC vaccine order. Abrysvo™ (NDC: 00069-0344-01) is provided through the VFC Program in a 1-pack, 1-dose vial. The minimum order quantity is 1 dose. Order enough doses needed for use in VFC eligible pregnant patients.

Please make sure your practice is prepared to store, label, and clearly identify adult RSV products to prevent misadministration. Per the Centers for Disease Control and Prevention (CDC), during the 2023–2024 RSV season, CDC received reports of GSK's Arexvy being administered in error to pregnant people. **Pfizer's Abrysvo is the only RSV vaccine recommended for pregnant people.** GSK's Arexvy and Moderna's mResvia are NOT approved for use during pregnancy and are not available for ordering through the VFC Program. Click here to [learn more](#) about misadministration errors during RSV maternal vaccination.



# VFC Shipments

- Flu, RSV and COVID orders are processed on a different line and typically arrive sooner than other routine vaccines
- In September, the VFC Program's national vaccine distributor, McKesson Specialty, experienced shipping delays for routine vaccine orders because of an unusually high volume of orders.
- Status of shipment delays by order type:
  - Flu Orders – Backlog (Return to current – Sept 30<sup>th</sup>)
  - Routine Orders – Backlog (Return to current – Oct. 2<sup>nd</sup>)
  - Frozen COVID-19 orders – Current
  - Frozen Varicella containing vaccines – Current
- **McKesson has indicated that all order lines should be up to date as of Wednesday, October 2.**
- The following steps were taken to mitigate the impacts of shipping delays:
  - McKesson is prioritizing delivery of items with RSV immunizations until the shipping delays resolve since providers are currently building inventory in advance of October vaccination.
  - McKesson is implementing weekend pick/pack and/or Sunday shipments to hasten the resolution of shipping delays. Keep in mind, vaccine shipments will only be delivered according to providers' stated delivery days and times.

# Poll: Barriers to Offering Nirsevimab?

1. Is your clinic offering nirsevimab?
  - Yes
  - No
2. Please share any challenges and barriers for your clinic to offer nirsevimab: [Choose all that apply.]
  - Cost/Reimbursement Issues
  - Immunization Management/Workflow Issues
  - Insufficient Number of Eligible Babies
  - Hesitancy
  - Complexity of Guidance
  - Lack of Information Around Benefits of Immunization
3. Other reasons / Comments [Write-in]



Elbie Reynoso

# Vaccines for Adults (VFA)

Lindsay Reynoso, CDPH





# VFA Ordering Reminder

 VFA Ordering will close EOD **Thursday, October 10, 2024**

As of 10/1/2024 – **80** Orders Submitted

- Reminder: VFA **does not** offer supplemental orders.
- **Q4 Ordering Policy:**
  - HPV vaccine is unavailable to order
  - Vaccine dose requests for PCV 20 and Shingrix will be capped at 40 doses
  - Caps for all other vaccines will remain the same
- **Next Ordering Cycle: January 2025**

## Have Questions of Need Assistance with Ordering?

Contact the Provider Call Center

Monday – Friday, 8AM-5PM

[ProviderCallCenter@cdph.ca.gov](mailto:ProviderCallCenter@cdph.ca.gov)

(833) 502 - 1245

Scout and Calder  
Volk



# Vaccine Management

Josh Pocus, My Turn

Maria Volk, myCAvax





# What's New in My Turn? – Release 53

New updates for Patients, Clinic Managers, and Vaccine Administrators launched on **Wednesday, October 2, 2024!**

## Release Highlights



My Turn Public

- ✓ Added 'Vaccines by Age' section on the My Turn home page
- ✓ New Hib, Pneumococcal (children), and Rotavirus vaccine information on the 'My Turn Public' portal
- ✓ Renamed 'Pneumonia (pneumococcal)' to 'Pneumonia (Pneumococcal) adults' vaccine
- ✓ New 'Hours of operation' section added on the Testing Site cards and Testing Site form
- ✓ Updated filters in the 'Find a Location' section on the 'Testing Sites' page
- ✓ Added 'Accepts walk-in patients' dropdown on the 'Vaccine Locator' page

## Release Highlights



My Turn Clinic

- ✓ New 'Insurance Status' dropdown added, replacing the 'Vaccine Brand' dropdown on the 'Appointments' page
- ✓ Added 'Insurance Status' and 'MediCal/Medicare' columns to the list view along with the revised column order on the 'Appointments' page
- ✓ New collapsible 'Optional: Pre-Populate Rows with Vaccine Information' section added on the Inline bulk upload flow
- ✓ New Hib, Pneumococcal (children), and Rotavirus vaccine added on the Digital Enrollment, Clinic Creation, VA, Walk-in, IIS, CQE, and Inline / CSV bulk upload flows
- ✓ Renamed 'Pneumonia (pneumococcal)' to 'Pneumonia (pneumococcal) adults' vaccine



# Testing Sites Cleanup / New Requirements

- To help ensure the public receives the **most relevant information** about your Testing Site, the My Turn team will be updating their testing site information form to require closing dates on all updates, and new sites.
- Testing sites will be **required** to provide a **start date** and **close date** on new site requests.
- Testing Sites will **need to re-verify** and update their close date **every 6 months** using the update form.
- Closing date will be limited to 6 months maximum.
- Testing Sites **must** provide new information by October 31, 2024, by adding a **new site** to the system, and making sure there is a close and start date added to your request.
  - Testing Sites that fail to provide this information, will be considered **inactive** and will no longer appear in My Turn.

**NOTE:** *Currently Close date is not required but after October 2nd it will be required. Any sites missing a closing date will need to be updated or risk being de-activated*



# Adding a Testing Site in My Turn

## How to add a Testing Site?

1. Go to the [Testing site information form](#).
2. On the top of the form, select **List a new location**.
3. Scroll down the form and select your **Hours of Operation, Starting Date** and **Closing date**.
4. Click **Submit** to create a new site.

If you have any questions or concerns, please call CDPH at 833-502-1245 or email [testinglocations@cdph.ca.gov](mailto:testinglocations@cdph.ca.gov).

**Testing site information**

To list, update, or delete a testing site location on My Turn, simply complete and submit the following form. It may take 3-5 business days for your request to go live on the My Turn site.

What would you like to do?  List a new location  Update a location  Delete a location

\*Requester's email address  
Please enter your business or public email only (no personal emails).  
john\_doe@clinic.com

\*Test site name  
ABC Clinic

\*Organization name

\*Test site address  
123 ABC St

\*City  
Los Angeles

\*County  
Los Angeles

\*Zip code  
90001

\*Test site phone number  
Ext.

\*Test site web page  
https://

**Hours of operation**  
Please select the hours of operations for your testing site below. You may only enter one time range per day.  
Do not display hours of operations on the location card.

Day(s) Open from Open to  
Monday, Tuesday 9:00 AM 10:00 AM

\*Starting date 5/18/2023 \*Closing date 9/18/2023

**Additional information**  
Holiday hours and closures, drive-thru testing, etc.



Please select the infections you offer testing and/or treatment for below. If you offer testing and/or treatment for infections that are not listed, please call CDPH at 1-833-502-1245 or email us at testinglocations@cdph.ca.gov.

\*This site offers testing for:  
\*This site offers treatment for:  
\*This site offers the following services:

Submit

# Provider Locator – Opt-In today!

Program Locations that have Opted-In:



Please take some time to opt-in, **preferably right now!** We want patients to be able to find you.

Data as of 10/3/24

# Provider Locator – Opt-In instructions

## How to Opt-In:

1. Log into myCAvax
2. Navigate to “Provider Locator” page
3. Navigate to the sub-page “My Turn Vaccine Locator Opt-In”
4. For each location, click the blue “Manage Vaccine Locator Form” button
5. Fill in the fields and press submit

The screenshot displays the myCAvax interface. At the top, there is a navigation bar with links for Home, My Programs, My Turn, Vaccine Orders, Program Locations, and More. A dropdown menu is open under 'More', showing options like Enrollment, Reports, myCAvax Dashboard, Provider Locator (highlighted with a red box and a blue circle '2'), and Knowledge Center. Below the navigation, the 'Provider Locator' section is active, with a sub-link 'My Turn Vaccine Locator Opt-In' highlighted with a red box and a blue circle '3'. The main content area is titled 'Opt-in to My Turn Vaccine Locator (Public-facing)' and includes a 'My Locations' section with a search filter set to 'Inactive'. A table below shows a location 'GVHC - 889 Abrego St - HS' with a 'Vaccine Locator Status' of 'Inactive'. A dropdown menu for 'Vaccine Locator' is open, showing a 'Manage Vaccine Locator Form' button highlighted with a red box and a blue circle '4'.

**NOTE:** To opt-out, click the “manage form” button for the location and select “No we do not accept new patients.” Then submit.

# myCAvax Release Roadmap

**Past Release**  
**August 15, 2024 (R49)**

## Release 49

### All Programs

- ✓ Enable storage unit management page for providers
- ✓ Enable look up program by PIN on orders
- ✓ Add VFC regions to Accounts and Program Locations
- ✓ New Home Page Knowledge Articles
- ✓ Allocations wrap up 24/25 season
- ✓ Provider staff management (Self-Service)
- ✓ SGF Enrollment updates

**Current**  
**September 19, 2024 (R50)**

## Release 50

### All Programs

- ✓ Supplemental Orders (Live as of 9/4)
- ✓ Self Service – Enable Organization Vaccine Coordinator
- ✓ Returns and Waste – Prevent excess Return Labels from being sent
- ✓ Prevent duplicate or invalid lot numbers on orders
- ✓ Provider Orders Will be sorted by most recently created
- ✓ Transfers updates including:
  - ✓ Batch accept/reject and layout updates
  - ✓ Updated language and additional information in the list view page
  - ✓ Ability for providers to update information when accepting a transfer
- ✓ Order processing enhancements

**Future**  
**October 16, 2024 (R51)**

## Release 51

### VFC

- ✓ Bulk Allocation

### VFC/VFA/317

- ✓ Corrections Needed orders will handle rejected line items and expired lots
- ✓ Field Reps will be notified when an order is placed with an open hold
- ✓ Only VtrckS Relevant changes will be sent to VtrckS
- ✓ Pending Status will now require a status reason
- ✓ Internal Comments will be saved as notes on an order instead of in the text box
- ✓ **Providers will see variance columns when creating orders**
- ✓ **Providers will be able to save progress on draft and corrections needed orders**
- ✓ Provider will only be able to have one open order at a time



# What's New in myCAvax? – Release 50

New updates for providers launched on **September 18, 2024!**

## Release Highlights



### Mass Update Order Status Enhancements

- ✓ Status changes made to a Batch Order will update the Order Line Item

### New Supplemental Orders

- ✓ Ability to place vaccine order requests before the Next Order Due Date\*

### Transfers page redesign

- ✓ Batch accept or reject transfer requests in the updated Transfers List View

### New field on the 'Staff Management Request' layout

- ✓ Added 'Manage Role' hyperlink for Organization Vaccine Coordinator role on the self-service page

### Batch Returns and Waste

- ✓ View 'Returns and Waste' parent record, which groups items into a batch and generates a universal return label

### Lot Number Enhancements

- ✓ Lot numbers must adhere to character restrictions and cannot be duplicated during ordering

### 40 Character Email

- ✓ Email addresses for Primary and Backup Vaccine Coordinator should be no more than 40 characters

### Account PIN Update

- ✓ Account PIN will be displayed on the Highlights panel on both the Location Account and Program Location pages

# myCAvax R50 - Transfer Enhancements

Vaccine transfers can be viewed at **Batch record** with **line items** of transferred products. This facilitates the acceptance of a transfer with multiple vaccine lines!

The screenshot displays the myCAvax interface for a vaccine transfer. At the top, there is a navigation bar with links for Home, My Programs, My Turn, Vaccine Orders, Program Locations, Vaccine Inventory, and More. The main content area shows a 'Vaccine Transfer' card with the ID 'VT-00000761' and buttons for '+ Follow' and 'Accept or Reject'. Below this, a summary table provides details about the transfer:



Status	Sending Program Location	Sending PIN	Receiving Program Location	Receiving PIN
New	<a href="#">Reshma's Rainbow Fountain - Vaccines for Children</a>	123497	<a href="#">Reshma's Unicorn Island - Vaccines for Children</a>	1

Below the summary, there are tabs for 'Details' and 'Related'. The 'Transfer Items' section is active, showing a table with the following data:

Line Item	Status	Transport Container...	Transport Container...	Vaccine	Number of doses Tr...	Lot #	Exp/Beyond Use Date
1	In Progress	1	Refrigerated Cooler	Bayfortus - 100mg - Sin...	1	123	2024-09-30

# myCAvax R50 - Transfer Enhancements

- Senders and Receivers can **edit transfers** while they are in progress.
- The **Primary and Backup** Coordinator from the sending location will receive an email when **changes** are made on the transfer.



Dear **Reshma's Unicorn Island - Vaccines for Children**,

Our records indicate that the receiving provider for [VT-00000670](#) has updated one or more of the following fields on the transfer you sent:

- Vaccine Group
- Vaccine Brand
- Presentation
- Doses Received

To review these updates, please log in to myCAvax and view this [VT-00000670](#).

If you have questions or require further assistance, please email [ProviderCallCenter@cdph.ca.gov](mailto:ProviderCallCenter@cdph.ca.gov) or call (877) 243-8832.

Vaccine Transfer  
VT-00000670

Status: New

Sending Program Location: Reshma's Rainbow Fountain - Vaccines for Children

Sending PIN: 120497

Receiving Program Location: Reshma's Unicorn Island - Vaccines for Children

Receiving PIN: 1

Please review and edit details of the transfer below and indicate if you accept or reject the transfer.

Transfer start date: 8/11/2024

Transfer start time: 12:00 AM

Number of transport containers: 1

### Transport Container

*Vaccine Group	*Vaccine Brand	*Presentation	*Lot Number	*Expiration Beyond use Date	*Doses Transferred	*Previously Transferred?	*Storage Unit/Brand
RSV	Bayortus (100mg)	Syringe - 1 mL	128	Sep 30, 2024	1	No	SC-87187 , vdtgrg

Comments:

**Transport container & temperature details upon arrival**

\*Temp of vaccines in transport container upon arrival:

\*Minimum temp of vaccines during transport:

\*Transfer End Date:

\*Vaccines exposed to out-of-range temps? Select an Option


**Accept or Reject**

\*Accept or Reject this transport container: In Progress

Cancel Submit

# Reminders for Transfers

- A transfer must be entered in myCAvax prior to the actual vaccine transfer.
- As soon as a transfer is received, the receiving provider must accept or reject the transfer in myCAvax.
- Transfers that remain in “Progress” will affect vaccine accountability if not completed prior to order submission!
- Over 50% of in progress VFC Transfers were created in August or earlier.





# myCAvax R50 – Batch Returns and Waste Enhancements

Returns and Waste Events will be **created** by Return or Wastage Type:

- **Expired**
- **Spoiled**
- **Wasted**

The screenshot shows the myCAvax VFC - Returns and Waste Events form. The form is titled "VFC - Returns and Waste Events" and includes a sub-header "Select Account and Enter Product Information". The form contains several input fields and a table for recording events.

**Program Location:** Reshma's Unicorn Island - Vaccines for Children

**Return or Wastage Type:** A dropdown menu with options: Expired, Spoiled, Wasted.

**Storage Unit:** Storage Unit

**NOTE:** Only report returns and waste events for program vaccines. Please do not report your privately purchased vaccines in myCAvax.

Vaccine Product Information					Waste Details	
*VaccineGroup	*Vaccine Brand	*Presentation	*Lot Number	*Expiration Date	*Total Doses Wasted	Clear Row
Select an Option	Select an Option	Select an Option				Clear Row

Buttons: Add Blank Row, Duplicate Returns and Waste Details

# myCAvax R50 - Lot Number Enhancements for Provider Ordering

The screenshot shows the 'Vaccine Products' section of the myCAvax R50 interface. The header includes 'Vaccine Products' and 'VFC On-hand Inventory'. The table below has columns for 'Vaccine product', '\*Quantity', 'Lot number', 'Expiration Date / Beyond use date', and '\*Qty sin'. A red error banner at the top states: 'Duplicate Lot Number found; include all doses in one line with the latest Expiration Date.' Below this, two rows for 'DTaP' 'Infanrix Single Dose Syringes - 10 Per Box' are shown. Both rows have a quantity of 5 and a lot number of '12345'. A red error message below each row reads: 'Duplicate lot number. Each lot number must be unique.'

- Providers will not be able to submit an order with a **duplicate** Lot Number
- Providers will not be able to submit an order with a Lot Number containing **special characters**
- Lot Number will be limited to **10 characters**

The screenshot shows the 'Vaccine Products' section of the myCAvax R50 interface. The header includes 'Vaccine Products' and 'VFC On-hand Inventory'. The table below has columns for 'Vaccine product', '\*Quantity', 'Lot number', 'Expiration Date / Beyond use date', and '\*Qty si'. A red error banner at the top states: 'Lot Number should include numbers, letters or dashes only; do not include special characters.' Below this, two rows are shown. The first row is for 'DTaP' 'Infanrix Single Dose Syringes - 10 Per Box' with a quantity of 5 and a lot number of '\*#&\*(^\$'. A red error message below the lot number reads: 'Only numbers, letters, and dashes are allowed.' The second row is for 'Kinrix Single Dose Syringes - 10 Per' with empty fields.

# Organization Vaccine Coordinator Overview



## Definition of role:

- The Organization Vaccine Coordinator (OVC) is a singular person who is responsible for overseeing compliance, ordering, training and implementation of program policies for multiple sites under one organization.



## Purpose of role:

- To have a key contact that can disseminate information throughout their organization in the instance that the individual Primary Vaccine Coordinator or Backup Vaccine Coordinator are in roles to guide policy at their locations.



## Policy:

- 1 OVC allowed per organization.
- If an organization wants to request more than one OVC for their organization, they can contact PCC via email with the rationale and all additional requests will be reviewed for approval on a case-by-case basis by CDPH leadership.



## Criteria:

- Active EZIZ training account required.
- Completion of EZIZ training required.



## Important call outs:

- An OVC will be added to all locations under the organization. You do not need to submit a request for each location.
- Requests can be submitted via Self Service Staff Management and require CDPH approval. Only one request can be submitted at a time. Self service for the OVC role is currently only available for VFC, VFA and LHD 317.

# Supplemental Order Reminder

**VFC**

**VFC - Order Request**

**Step 1 - Select Account and Product**

To change the program selected, navigate back to the [Vaccine Orders page](#).

\* Program Location

Reshma's Unicorn Island - Vaccines for Children

**Select Location, Provide Inventory and Doses Administered for Vaccines listed.**

- Ensure the current VFC inventory in your vaccine storage units matches the On-hand Inventory you enter.
- Your VFC Doses Administered inventory must match the immunization registry (CAIR/Healthy Futures).
- View the provider inventory link below to account for every dose your location has received. If your calculated provider inventory does not match, please ensure that you have reported all transfers, waste events, and returns prior to this order request.

1	Next Order Due Date (approximate) ⓘ	Provider Inventory ⓘ	Practice Volume & Order Frequency ⓘ
	October 23, 2024	<a href="#">View Provider Inventory</a>	Every 3 months

[Chat with us](#)

2

**You are ordering outside of your routine order frequency.**

Why are you placing this order? (select all that apply)

- Seasonal vaccines
- Increased patient demand
- Increased vaccine administration
- Insufficient doses ordered with last order
- Clinicians added to our clinic
- Other

**Your last order was processed more than 30 days ago. Full inventory reporting and doses administered is required.**

This functionality is available as of **September 5, 2024.**

1. Providers can place vaccine order requests **before their Next Order Due Date.**
2. Providers **must** select, using the checkbox, one or more reasons to **justify** placing an order outside the standard ordering window.

## Important Reminder:

If providers **do not** select this checkbox, they will receive an error message when trying to submit their supplemental order and the order **will not be completed.**



# Viewing Support Resources

**Home**  
Vaccine Programs  
Vaccine Management  
Storage Units  
Temperature Monitoring  
Training & Webinars  
Clinic Resources  
Patient Resources  
Contact VFC  
Phone: (877) 243-8832  
Hours:  
Mon-Thurs, 9AM-4:30PM  
Friday, 9AM-4PM  
Send us an email  
Fax: (877) 329-9832  
VFC Field Representatives  
Find VFC providers  
Sign up for EZIZ emails  
Frequently Asked Questions

**Move to myCAvax**

**VFC vaccine ordering moved to myCAvax on June 10, 2024!**

The Vaccines for Children (VFC) Program moved its vaccine ordering and provider management system to myCAvax, on June 10, 2024. Use myCAvax to view/submit vaccine orders and report transfers, waste, returns, temperature excursions and shipping incidents!

**Reminder:** The following ordering policies/procedures remain the same:

- Report doses administered and on hand inventory on each order
- Timeframes for order submission and order processing will not change
- Vaccine Coordinators receive email confirmations once orders are approved and are being filled by McKesson or directly (Merck/Pfizer)
- Provider can request shipping labels for returning doses

**Starting June 10, log in to myCAvax!**

Primary and backup vaccine coordinator will receive a myCAvax welcome email on June 10, 2024, which will ask them to finish setting up their myCAvax account. (Unique login credentials will be created using Vaccine Coordinators information from MyVFCvaccines).

- Log in to myCAvax to familiarize yourself with all VFC functions now available!
- Submit vaccine orders in myCAvax!
- Attend Office hours as needed.
  - Note: Existing myCAvax users will see a new VFC Program tile upon logging in. Access all the new VFC functions available to you there.

For existing myCAvax users:

The VFC program will be added to your account on June 10, 2024.

- Update storage units as soon as possible in myCAvax. Make a new storage unit and indicate that VFC vaccines are stored in it OR add the VFC Program to the storage unit accordingly (if your VFC vaccine is stored in a storage unit already tracked in myCAvax). For more information on updating/adding storage units, view the Managing myCAvax Provider Accounts job aid on the Knowledge Center (myCAvax login required).

All Vaccine Coordinators will be able to complete the following VFC activities for their VFC locations:

- View and place orders
- View and place transfers
- View and report waste or returns
- Report shipping incidents

If an additional Vaccine Coordinator needs to be added to your account to complete the above activities, please fill out this online form: [Additional Vaccine Coordinator Request Form](#).

**Recorded Trainings and FAQs:**

All VFC providers should attend the following trainings. Multiple sessions will be offered for each training. Please see the registration links provided below to sign up for available sessions.

- Getting Started with myCAvax for Brand New Users | FAQ
  - Wednesday May 22, 2024, from 10:00-10:30am | Recording and deck
  - Wednesday May 29, 2024, from 9:00-9:30am | Recording and deck
  - Tuesday June 4, 2024, from 12:30-1:00pm | Recording and deck
  - Friday June 7, 2024, from 11:30am-12:00pm | Recording and deck
  - Zoom registration link

VFC Provider Training FAQs v.2\_06.03.24

**VFC Provider Training FAQs**

... is to support VFC providers through the transition from MyVFCvaccines to myCAvax. For the latest transition updates, visit [EZIZ](#).

... a category to be directed to related FAQs.

Introduction	2
myCAvax	2
Account Management	3
Vaccine Management	4
...	5
...	7
...	7

View VFC training recordings, decks and FAQs on EZIZ's [Get Ready to Move page](#).

For Program and Policy needs, you can contact the VFC Customer Service Center at (877) 243-8832 or via email to [MyVFCvaccines@cdph.ca.gov](mailto:MyVFCvaccines@cdph.ca.gov). For myCAvax Technical Support, contact the Provider Call Center by calling the VFC Customer Service Center and selecting option 9 on the phone tree, or via email to [myCAvax.HD@cdph.ca.gov](mailto:myCAvax.HD@cdph.ca.gov).



# Resources and Q&A


Leslie Amani, CDPH



# Resources on EZIZ

- Home
- Vaccine Programs
- Vaccine Management
- Storage Units
- Temperature Monitoring
- Training & Webinars
- Clinic Resources
- Patient Resources

[Link to EZIZ Homepage](#)



ENHANCED BY Google

*A one-stop shop for immunization training and resources.*

Home

Vaccine Programs

Vaccine Management

Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources

**California's Vaccine Programs**




California Vaccines for Children Program



California Vaccines for Adults Program



California Bridge Access Program



Local Health Department 317 Program

**Ordering & Vaccine Management**

- MyCAvax (VFC, VFA, BAP, and 317)
- MyVFCvaccines (read-only)

**Storage Requirements**

- Vaccine Storage Units
- Digital Data Loggers

**Hot Topics**



**CDPH Immunization Updates for Providers**

- AIM Champion Awards
- S&H Job Aids for VFC, VFA, LHD 317 and SGF programs
- Reporting & Return of Nonviable Vaccines
- Reporting Excursions & Manufacturer Contacts
- COVID-19 Vaccine Resources
- VFC and Birthing Hospitals

**Contact VFC**

Phone: (877) 243-8832  
Hours: Mon-Thurs, 9AM-4:30PM  
Friday, 9AM-4PM  
Send us an email  
Fax: (877) 329-9832

- ▶ VFC Field Representatives
- ▶ Find VFC providers
- ▶ Sign up for EZIZ emails
- ▶ Frequently Asked Questions

**Alerts!**



**2024-25 COVID Vaccine**

- COVID-19 Vaccine Timing Guide (8/30/24)
- Calendario de la Vacuna COVID-19 (9/10/24)
- COVID-19 Vaccine Product Guide (9/9/24)
- More Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturing Info



**VFC vaccine ordering and management is now live at myCAvax!**

- Learn more about myCAvax move, recorded trainings and FAQs!



**Holiday Ordering and Distribution for SGF**

- September/October Calendar

VFC Memos

Vaccine Order Status

From CDPH

**VFC Program Letters**

- VFC 2024-2025 Flu Vaccine Ordering Information September 6
- myCAvax is Now the VFC Vaccine Management System June 14
- Clinical Letter for Penbraya (MenABCWY vaccine) May 16
- VFC is Moving to a New Vaccine Management System – myCAvax May 13

**Popular Resources**

**Protect Your Patients Against RSV!**

- ▶ RSV Immunization FAQs
- ▶ Resources for Providers and Patients

**Vaccine Resources**

- ▶ Vaccine Fact Sheets
- ▶ Flu
- ▶ Measles
- ▶ Mpox
- ▶ Pertussis
- ▶ Schedules & Recommendations
- ▶ For Pharmacies

**CDPH Applications**

- ▶ myCAvax (ordering and management)
- ▶ MyVFCvaccines (read-only)
- ▶ My Turn (COVID/Flu Vaccine Administration System)
- ▶ CAIR (California Immunization Registry)
- ▶ My DVR (Digital Vaccine Records)
- ▶ CAIR-ME (Medical Exemptions from Immunizations for School and Child Care)

Updated  
9.27.24

# Provider FAQs

## COVID-19 Vaccine and Therapeutics FAQs

For providers administering COVID-19 vaccine and treating COVID-19. Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

- [New and Updated FAQs](#)..... 2
- [COVID-19 Vaccine Access](#)..... 2
- [California Bridge Access Program \(BAP\)](#) ..... 5
- [Vaccines For Children \(VFC\) Program](#) ..... 6
- [Vaccine Administration](#)..... 7
- [Vaccine Storage & Handling](#)..... 10
- [Reporting](#)..... 11
- [COVID-19 Therapeutics](#)..... 13
- [Support & Resources](#) ..... 14



**New** Q: *What is the California Bridge Access Program (CA BAP) extension?*

A: The CA Bridge Access Program (CA BAP) is providing COVID-19 vaccines at no-cost to uninsured and underinsured adults ages 19 years and older during the 2024 – 2025 respiratory season.

**New** Q: *How are participation, eligibility, and all other Bridge Access Program requirements changing with the CA Bridge Access Program (CA BAP) extension?*

A: Participation, eligibility, and all other CA BAP requirements remain unchanged. [Provider agreements](#) are being extended with the extension of [CA BAP](#): No action from providers is required at this time.

**New** Q: *Where can providers find more information about the CA BAP extension?*

A: For CA BAP information on provider participation, reporting, ordering, and product information, refer to the following resources:

- EZIZ's [CA BAP Overview](#) and [Resources](#) webpages
- [CA BAP Requirements at a Glance](#)
- [CA BAP Provider Operations Manual](#) (CA BAP POM)
- [COVID-19 Vaccine Product Guide](#)
- [COVID-19 Vaccine Timing Guide](#)
- [CA BAP Weekly Ordering Cadence Calendar](#)

[Link to COVID-19 Provider FAQs](#)





# COVID-19 Vaccine Product Guide 2024 – 2025

COVID-19 Vaccine Product Guide					CDPH
<b>Check vaccine labels and FDA materials before use to avoid mix-ups.</b>					
Package inserts and EUA fact sheets supersede info on vials and carton.					
<b>Pfizer</b>					
	<b>Infant/Toddler 6 months–4 years</b>	<b>Pediatric 5-11 years</b>	<b>Comirnaty 12+ years</b>	<b>Comirnaty 12+ years</b>	
			Single-Dose Vial 2024-25 Formula image not available		
	2024-25 Formula	2024-25 Formula		2024-25 Formula	
<b>Packaging</b>	Yellow Cap	Blue Cap		Pre-Filled Syringe	
Doses Per Vial	3 doses	1 dose	1 dose	1 dose/syringe	
Carton Size	30 doses	10 doses	10 doses	10 doses	
<a href="#">NDC-Unit of Sale (carton)</a>	59267-4426-02	59267-4438-02	00069-2403-10	00069-2432-10	
<a href="#">NDC-Unit of Use (vial/syringe)</a>	59267-4426-01	59267-4438-01	00069-2403-01	00069-2432-01	
CVX Code	308	310	309	309	
CPT Code	91318	91319	91320	91320	
Program Availability	VFC	VFC	Not available	VFC, CA BAP	
Min. Standard Order*	30 doses	10 doses	N/A	10 doses	
<b>Storage Limits Before Puncture:</b> Label vaccine with expiration and use-by dates.					
Shipping	Ships from manufacturer with dry ice between -90°C and -60°C (-130°F to -76°F)			<b>2° to 8°C (36°F to 46°F)</b>	
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)				
Thermal Shipper					
Freezer					
Refrigerator	Up to 10 weeks at 2°C to 8°C (36°F to 46°F). Do not refreeze. Write the use-by date on carton—not to exceed expiration.			Until expiration at 2°C to 8°C	
Expiration Date	Check the date on the product/carton, or for thawed products refer to the written use-by date.			Check label.	
<b>Administration</b>					
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute	N/A	
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose	0.3 mL 30 mcg dose	
Refrigerator Thaw Time	Carton/Vial: Up to 2 hours at 2° to 8°C (36°F to 46°F) (Do not refreeze)			N/A	
Room Temp Thaw Time	Vial: 30 minutes at up to 25°C (77°F) (Do not refreeze)			N/A	
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)				
<b>Storage Limits After Puncture (Multi-dose vials):</b> Record puncture and use-by time on vial label.					
Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A	Use immediately after removing cap, within 4 hours.	
* Orders for privately purchased vaccines may have different order minimums.					
California Department of Public Health, Immunization Branch			IMM-1399 (9/24/24) Page 1 of 3		

COVID-19 Vaccine Product Guide			CDPH
	<b>Moderna</b>		<b>Novavax</b>
	<b>Pediatric 6 months–11 years</b>	<b>Spikevax 12+ years</b>	<b>Adol/Adult 12+ years</b>
	2024-25 Product	2024-25 Product	
<b>Packaging</b>	Pre-Filled Syringe	Pre-Filled Syringe	Pre-Filled Syringe
Doses Per Vial	1 dose/syringe	1 dose/syringe	1 dose/syringe
Carton Size	10 doses	10 doses	10 doses
<a href="#">NDC-Unit of Sale (carton)</a>	80777-0291-80, Blister-sealed: 80777-0291-81	80777-0110-96, Blister-sealed: 80777-0110-93	80631-0107-10
<a href="#">NDC-Unit of Use (vial/syringe)</a>	80777-0291-09	80777-0110-01	80631-0107-01
CVX Code	311	312	313
CPT Code	91321	91322	91304
Program Availability	VFC	VFC, CA BAP	VFC, CA BAP
Min. Standard Order*	10 doses	10 doses	10 doses
<b>Storage Limits Before Puncture:</b> Label vaccine with expiration and use-by dates.			
Shipping	Ships frozen between -50°C and -15°C (-58°F and 5°F)		2° to 8°C (36° to 46°F)
ULT			
Thermal Shipper			
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)		
Refrigerator	Up to 60 days (not to exceed expiration date) at 2–8°C (36–46°F)		Until expiration at 2–8°C (36–46°F)
Expiration Date	Check <a href="#">Moderna product website</a> or QR code.		<a href="#">Check product website.</a>
<b>Administration</b>			
Diluent	N/A		N/A
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50 mcg	0.5 mL 50 mcg
Refrigerator Thaw Time at 2°C to 8°C (36°F to 46°F) (Do not refreeze)	Syringe: 1 hour Carton: 2.5 hours		N/A
Room Temp Thaw Time at 15° to 25°C (59° to 77°F) (Do not refreeze)	Syringe: 45 minutes, Carton: 2 hours and 15 minutes		N/A
Total Room Temp Time	Store up to 12 hours at 8°C to 25°C (46°F to 77°F)		N/A
<b>Storage Limits After Puncture</b>			
Use-By Limit	N/A. Discard after single use.		N/A. Discard after single use.
California Department of Public Health, Immunization Branch			IMM-1399 (9/24/24) Page 2 of 3

COVID-19 Vaccine Product Guide				CDPH
<b>Do Not Use Deauthorized Products:</b>				
Use only COVID-19 vaccine products updated for 2024-25.				
<b>Pfizer</b>				
<b>Infant/Toddler 6 months–4 years</b>	<b>Pediatric 5–11 years</b>	<b>Adol/Adult (Comirnaty) 12+ years</b>		
2021 Monovalent	Bivalent	2023-24 Monovalent	Bivalent	
		2023-24 single-dose vial	2023-24 syringe	
<b>Moderna</b>				
<b>Infant/Toddler 6 months–5 years</b>	<b>6 months+</b>	<b>Pediatric 6–11 years</b>	<b>Pediatric 6 mos–11 yrs</b>	
2021 Monovalent	Bivalent	2021 Monovalent	2023-24 single-dose vial	
		2021 Monovalent	2023-24 single-dose vial	
		2023-24 syringe	2023-24 syringe	
<b>Novavax</b>				
<b>Primary 12+ yrs Booster 18+</b>				
2022 Monovalent				
2023-24 multi-dose vial				
<b>Janssen (J&amp;J)</b>				
<b>Adult 18+ years</b>				
2021 Monovalent				
California Department of Public Health, Immunization Branch				
IMM-1399 (9/24/24) Page 3 of 3				

# COVID-19 Vaccine Timing 2024 – 2025

## COVID-19 Vaccine Timing 2024-25 –Routine Schedule

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2024-25 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8** weeks 1 ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 4-8 weeks 1 If ≥2 prior doses then: ≥8 weeks 1
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months <b>2024-25 Formulation:</b> Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months <b>2024-25 Formulation:</b> Moderna/Pfizer/Novavax
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax	1st Dose → 3-8 weeks** → 2nd Dose	

\* See [CDC recommendations](#) for children transitioning from a younger to older age group  
 † Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.  
 \*\* An 8-week interval may be preferable for some people, especially for males 12-39 years.  
 † All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).  
 ‡ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.



## COVID-19 Vaccine Timing 2024-25 if Moderately/Severely Immunocompromised

Age	Vaccine	If unvaccinated:	If had any prior doses give 2024-25 doses:
6 months–4 years	Pfizer Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 3 w 1 ≥8 w 2 ≥2 prior doses: ≥8 w 1 ≥2 m
	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m
5–11 years	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer	≥3 prior doses**: ≥8 w 1 (for ages 5+ yrs, Pfizer dose is also OK)
	Pfizer–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer	1 prior dose: 3 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥2 m
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	≥3 prior doses**: ≥8 w 1 ≥2 m
	Moderna–Adol/Adult (Spikevax)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥3 prior doses**: ≥8 w 1 ≥2 m
	Novavax	1st Dose → 3 weeks → 2nd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	≥1 prior doses**: ≥2 m 1 ≥2 m

\* An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See [Table 2](#) for vial and dosage.  
 \*\* Ages 5-11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax.

California Department of Public Health, Immunization Branch

IMM-1396 (8/30/24) Page 2 of 2

## Updated COVID-19 Vaccine Timing Guide

# Vaccine Support

## Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.


- For myCAvax Help Desk inquiries: [myCAvax.hd@cdph.ca.gov](mailto:myCAvax.hd@cdph.ca.gov)
- For My Turn Clinic Help Desk inquiries: [MyTurn.Clinic.HD@cdph.ca.gov](mailto:MyTurn.Clinic.HD@cdph.ca.gov)
- For all other inquiries: [providercallcenter@cdph.ca.gov](mailto:providercallcenter@cdph.ca.gov)
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

## myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.



Need help? View our job aids in the [Knowledge Center](#), or [contact us](#).



# COVID-19 Therapeutics Resources

Type of Support

Description

Updated 7.8.24



## Clinical Guidance

For general Therapeutics questions, please email: [cdphtherapeutics@cdph.ca.gov](mailto:cdphtherapeutics@cdph.ca.gov)



## General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[Finding COVID-19 Treatments](#) (questions and answers for the public on finding COVID-19 treatments)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more for providers)

[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



## Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (find COVID-19 medications near you)
- [Information Page for Test-to-Treat](#) Program (hhs.gov)



## [Archive LHD Therapeutics SharePoint](#)

For access to previously recorded LHD webinars and slides contact: [rphoadmin@cdph.ca.gov](mailto:rphoadmin@cdph.ca.gov)

For Information on how to registers for HPOP reporting information, use link below.

- [CDPH Therapeutics HPOP Account Verification & Reporting](#) information



## Questions

For general CDPH Therapeutics questions, please email [cdphtherapeutics@cdph.ca.gov](mailto:cdphtherapeutics@cdph.ca.gov)

For ordering, program inquiries, signing up new HPOP Accounts: please e-mail [cdphtherapeutics@cdph.ca.gov](mailto:cdphtherapeutics@cdph.ca.gov)

# CDPH Provider Webinars and Trainings

## Week of October 7, 2024

	Monday 10/7	Tuesday 10/8	Wednesday 10/9	Thursday 10/10	Friday 10/11
Live Webinars and Training	No Events Scheduled at this time				

View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Immunization Branch Archived Provider Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>	<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding</a> (v. 1/4/22)</li> <li><a href="#">Latest Features in My Turn</a> (Requires myCAvax Login)</li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users</a> (Requires myCAvax Login)</li> </ul>
----------------	---	--

<b>Help</b>	<b>Help Desk</b>	<b>Immunization Resources</b>
	<p><b>CDPH Provider Call Center:</b> 1-833-502-1245, M-F 8am-5pm Email: <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a></p> <p><b>My Turn:</b> Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a> Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a></p> <p><b>myCAvax:</b> Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a>      <b>Mpox:</b> Email: <a href="mailto:stxcb@cdph.ca.gov">stxcb@cdph.ca.gov</a></p>	<p><a href="#">California's General Immunization Resources (eziz.org)</a></p> <p><a href="#">RSV Immunization Resources</a>      <a href="#">Flu Vaccination Resources</a></p> <p><a href="#">COVID-19 Vaccination Resources</a>      <a href="#">COVID-19 Treatments</a></p> <p><a href="#">Mpox Vaccination Resources</a></p>



# CDPH Provider Webinars and Trainings

## Week of October 14, 2024

	Monday 10/14	Tuesday 10/15	Wednesday 10/16	Thursday 10/17	Friday 10/18	
Live Webinars and Training					<a href="#">CDPH Immunization Updates for Providers</a> 9:00 am – 10:30 am	
View On Demand	<ul style="list-style-type: none"> <li><a href="#">CDPH Immunization Branch Archived Provider Webinars and Slides</a></li> <li><a href="#">AIM Vaccine Confidence Toolkit Webinar Series</a></li> </ul>		<ul style="list-style-type: none"> <li><a href="#">Introduction to My Turn Onboarding</a> (v. 1/4/22)</li> <li><a href="#">Latest Features in My Turn</a> (Requires myCAvax Login)</li> <li><a href="#">myCAvax Release Notes for LHD and CDPH Users</a> (Requires myCAvax Login)</li> </ul>			
Help	<p><b>Help Desk</b></p> <p><b>CDPH Provider Call Center:</b> 1-833-502-1245, M-F 8am-5pm Email: <a href="mailto:providercallcenter@cdph.ca.gov">providercallcenter@cdph.ca.gov</a></p> <p><b>My Turn:</b> Help Desk Email: <a href="mailto:myturn.clinic.hd@cdph.ca.gov">myturn.clinic.hd@cdph.ca.gov</a>            Onboarding Email: <a href="mailto:myturnonboarding@cdph.ca.gov">myturnonboarding@cdph.ca.gov</a></p> <p><b>myCAvax:</b> Help Desk Email: <a href="mailto:mycavax.hd@cdph.ca.gov">mycavax.hd@cdph.ca.gov</a>      <b>Mpox:</b> Email: <a href="mailto:stdcb@cdph.ca.gov">stdcb@cdph.ca.gov</a></p>			<p><b>Immunization Resources</b></p> <p><a href="#">California's General Immunization Resources (eziz.org)</a></p> <p><a href="#">RSV Immunization Resources</a>      <a href="#">Flu Vaccination Resources</a></p> <p><a href="#">COVID-19 Vaccination Resources</a>      <a href="#">COVID-19 Treatments</a></p> <p><a href="#">Mpox Vaccination Resources</a></p>		

# Thank you for Attending!

## Upcoming Webinar Opportunities

[CDPH IZB Bi-weekly Updates for Providers](#)

Next session: Friday, October 18, 2024

9:00 am – 10:30 am, PT

